Fig. 4: Radiolabeled PU-HZ151 detects epichaperome-positive lesions of the CNS.
From: Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system
a Experimental design to detect through PET imaging epichaperome-positive CNS lesions. Representative whole-body serial PET/CT images of mice as in b are also shown. b PET determined time-dependent concentration of [124I]-PU-HZ151 in intracranial epichaperome+ve (MDA-MB-468) tumors and in the surrounding, unaffected brain. Serial PET/CT images were obtained at the times indicated after single intravenous infusion of a microdose of [124I]-PU-HZ151 (15 µCi g−1). PET/CT image of representative mice obtained at 48 h post-[124I]-PU-HZ151 injection is also shown. Data, mean ± s.e.m., n = 5, two-way ANOVA, p < 0.0001, F(1,40) = 91.62. c, d Representative digital autoradiography ([131I]-PU-AD, 15 μCi g−1 iv, 6 h post-injection) (c) and H&E staining (d) of cryosections from brains as in b. The relative area occupied by the brain tumor is shown with a blue line. Inset in d shows the heterogeneity of the tumor with clusters of cancer cells surrounded by stroma. Scale bar, 2 mm. Inset scale bar, 100 μm. e PET scan of the mouse as in c, d, imaged and as in b, prior to killing. For (b–e) mice were first injected with [124I]-PU-HZ151 and imaged up to 72 h. On the day following the last PET-scan, when [124I]-PU-HZ151 was cleared, mice were injected [131I]-PU-AD for autoradiography. The same sections were subsequently subjected to H&E staining for morphological evaluation of tissue pathology and to compare the localization of the epichaperome probe with the location of epichaperome-positive tumor tissue. Source data are provided as a Source Data file.
